US FDA approves Sanofi's drug for a rare blood disorder

Sanofi has secured FDA approval for Wayrilz (rilzabrutinib), its drug for chronic immune thrombocytopenia (ITP), validating the company's $3.7 billion acquisition of Principia Biopharma and advancing its strategic pivot towards rare disease and immunology. Analysts project peak sales for Wayrilz, which targets an unmet need in ITP, could reach $2 billion to $5 billion. The drug, priced at $17,500 per month, is set for U.S. market availability in September, bolstering Sanofi's growth trajectory beyond its top-selling Dupixent.

Analysis

The U.S. FDA's approval of Sanofi's drug Wayrilz (rilzabrutinib) for chronic immune thrombocytopenia (ITP) represents a significant strategic victory and a key de-risking event for the company. This approval serves as the first major validation of its $3.7 billion acquisition of Principia Biopharma in 2020, providing a clear path to generating returns on that investment. With analyst peak sales projections ranging from $2 billion to $5 billion, Wayrilz is positioned to become a substantial growth driver, directly supporting Sanofi's objective to build a formidable rare disease and immunology franchise and reduce its long-term dependence on its top-selling drug, Dupixent. The drug's launch, scheduled for September with a list price of $17,500 per month, targets a specific unmet need in patients who have failed prior ITP treatments, suggesting a strong initial market and a high-value pricing strategy.

Key Decisions for Investors

• The FDA approval for Wayrilz materially de-risks Sanofi's pipeline and validates its $3.7 billion Principia Biopharma acquisition, creating a potential multi-billion dollar revenue stream that diversifies the company away from its reliance on Dupixent.
• Investors should now shift focus to the commercial execution of Wayrilz, monitoring initial sales uptake and management commentary on payer reimbursement, as achieving the forecast $2-5 billion in peak sales is contingent on successful market access at its premium price point.
• While the news is neutral for Regeneron, it underscores Sanofi's long-term strategy to diversify, which could eventually alter the strategic dynamics of the Dupixent partnership and should be considered a long-term factor for REGN investors.